NCT04488159 2024-09-20
iMAGINE
Medical University of Vienna
Phase 3 Withdrawn
Clinical Trials
31 trialsNCT04029857 2024-02-13
Nutritional Supplementation in Reducing Complications in Patients With Locally Advanced Esophageal Cancer Undergoing Chemotherapy, Radiation Therapy, and/or Surgery
M.D. Anderson Cancer Center
Phase 3 Withdrawn
NCT02519140 2023-12-04
Assessing How the Viscosity of Submucosal Gel Injections Helps With Endoscopic Mucosal Resections
Maimonides Medical Center
Phase 3 Withdrawn
NCT02201381 2022-07-18
METRICS
Health Clinics Limited
Phase 3 Withdrawn
NCT04465734 2022-05-05
A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC
Shanghai Henlius Biotech
Phase 3 Withdrawn
NCT04859582 2021-12-16
KEYNOTE-859
Merck Sharp & Dohme LLC
Phase 3 Withdrawn
NCT04151719 2021-05-07
An Extension Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer
Bausch Health Americas, Inc.
Phase 3 Withdrawn
NCT02326779 2021-04-27
Low-dose Aspirin Therapy for Esophageal Cancer
Zhejiang University
Phase 3 Withdrawn
NCT03649035 2021-03-19
Eus-guided Cryothermal Ablation in Stage III Pancreatic Adenocarcinoma
Istituto Clinico Humanitas
Phase 3 Withdrawn
NCT02597465 2020-12-14
A Randomized, Open-Label, Comparative, Parallel-Group, Multicenter Study of SPARC1507
Sun Pharma Advanced Research Company Limited
Phase 3 Withdrawn
NCT04546802 2020-09-14
HATCHeT
Bayside Health
Phase 3 Withdrawn
NCT03579758 2020-06-05
Chemotherapy Before & After Surgery in Patients With Resectable Gallbladder Cancer
Emory University
Phase 3 Withdrawn
NCT03881111 2020-02-11
KEYNOTE-590
Merck Sharp & Dohme LLC
Phase 3 Withdrawn
NCT01470742 2019-12-30
Trial Comparing Capecitabine Plus Oxaliplatin (XELOX) and Capecitabine (X) as First-line Chemotherapy in Elderly Patients With Advanced Gastric Cancer
Samsung Medical Center
Phase 3 Withdrawn
NCT02736552 2019-05-08
Compare S-1 for 6 Months to 1 Year as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Staged II , IIIA or IIIB.
Fudan University
Phase 3 Withdrawn
NCT03744247 2019-05-02
Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC
Sun Yat-sen University
Phase 3 Withdrawn
NCT03791918 2019-05-02
Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria
Sun Yat-sen University
Phase 3 Withdrawn
NCT03717038 2019-02-04
Sym004 Versus TAS-102 in Patients With mCRC
Symphogen A/S
Phase 3 Withdrawn
NCT02149771 2018-04-19
Combination Treatment for Advanced Liver Cancer
Shanghai Zhongshan Hospital
Phase 3 Withdrawn
NCT01338558 2016-11-02
A Study of Avastin (Bevacizumab) in Combination With mFOLFOX6 in Treatment-Naïve Patients With Metastatic Colorectal Cancer With or Without K-RAS Mutations, and Comparison to Cetuximab
Hoffmann-La Roche
Phase 3 Withdrawn
NCT02004210 2016-04-27
A Phase 3 Trial Comparing TACE and TARE in Unilobar Advanced Hepatocellular Carcinoma
Seoul National University Hospital
Phase 3 Withdrawn
NCT01622803 2016-04-26
Comparison Between Two Methods of Bilateral Stenting for Malignant Hilar Obstruction
Samsung Medical Center
Phase 3 Withdrawn
NCT01998347 2015-11-20
Paclitaxel Liposome and Cisplatin as First-line Chemotherapy in Patients With Metastatic Esophageal Cancer
Shantou University Medical College
Phase 3 Withdrawn
NCT01422928 2015-05-25
Acupuncture for the Immune System in Radiation Cancer Patients
British Columbia Cancer Agency
Phase 3 Withdrawn
NCT01245816 2015-04-24
A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)
Cancer Prevention Pharmaceuticals, Inc.
Phase 3 Withdrawn
NCT00253617 2013-04-04
Stent Placement With or Without Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Treating Patients With Stage III or Stage IV Cholangiocarcinoma That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 3 Withdrawn
NCT01786538 2013-03-13
Second-line FOLFOX With or Without Regorafenib in mCRC Patients Failed to First-line Irinotecan Plus Fluoropyrimidines
Asan Medical Center
Phase 3 Withdrawn
NCT01327521 2012-06-11
Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma
Stanford University
Phase 3 Withdrawn
NCT01209013 2012-05-08
Oedisse
Pinnacle Biologics Inc.
Phase 3 Withdrawn
NCT01318200 2012-02-20
Transarterial Chemoembolization (TACE) vs. CyberKnife for Recurrent Hepatocellular Carcinoma (HCC)
Accuray Incorporated
Phase 3 Withdrawn
NCT01245582 2011-11-09
SECOX
Sanofi
Phase 3 Withdrawn